To the Editor: A billion-dollar question is whether precision medicine (also known as personalized, 'P4' or systems medicine) can substantially increase the utility of individualized disease prevention and population health 1, 2 . In this respect, the first results from the Pioneer 100 Wellness Project (P100), featured in last August's issue, is a landmark 3, 4 . The study sheds light on an approach that has primarily existed as a vision and precedes the US National Institutes of Health's (NIH; Bethesda, MD) All of Us study, which will include a million participants in a similar scheme (http://www. allofus.nih.gov/). The researchers behind the study claim to demonstrate how measurement of personal data clouds over time can improve our understanding of health and disease and to identify "actionable possibilities" by which individuals can enhance health through preventive strategies.
P100 is an exploratory study of associations in networks of biomarkers and risk factors established from large and dynamic data clouds of 108 participants. Over the course of a 9-month period, participants underwent whole-genome sequencing (yielding 127 polygenic scores for disease risks plus three copy number variations); testing of metabolome (643 metabolites), proteome (262 proteins) and microbiome (4,616 taxonomic units) three times; 218 other clinical tests and measurements; and daily activity tracking via 'quantified self ' technologies. Associations between these biomarkers yielded a total of 3,470 connections in a correlation network. The P100 study is a project designed to display the potentials for novel technologies and gather support for precision or P4 medicine (predictive, preventive, personalized and participatory), and it has received prominent publicity in Nature 5 . The P100 will also be scaled up to include Precision medicine in the clouds 100,000 participants in the 100K Wellness Project 3 . Against this background, we provide our view of whether the P100 study actually supports the prospect of substantial benefits from data-driven disease prevention and argue that it presents severe challenges.
The graphics of the correlational networks presented by Price et al. 3 do offer an interesting research potential for exploring connections in molecular networks and for identifying candidate biomarkers 3 . However, as yet there are only a few examples where such approaches have led to discoveries of therapeutic potential, especially when it comes to disease prevention, which is the main aim of P100. Systems medicine has very ambitiously been promoted as a "holistic" approach that will "tackle all components of the complexity of non-communicable diseases" 6 . It is, of course, not obvious that scientific models can ever encompass all factors that will determine an individual's health. The P100 also illustrates that the purportedly holistic ambition of quantitative systems medicine is far from being realized as it employs a reductionist method defined less by true integration than by collection and correlation of diverse, but mostly molecular, data.
In terms of its approach as a clinical research method, the P100 does not involve a classic randomized trial with a control group. Instead it opts for an ambitious, but ill-defined, n-of-1 approach whereby each participant is extensively monitored and considered his or her own control. To quote Leroy Hood: "We hope to develop a whole series of stories about how actionable opportunities have changed the wellness of individuals" 5 . In line with this reasoning, the authors present changes in clinical biomarkers during the 9-month study as evidence for clinical utility. However, to measure an unbiased, valid effect in an n-of-1 randomized clinical trial, the study would have to include pairs of organized periods so that one period of each pair applies the experimental therapy and the other period applies usual care or placebo, and both the clinician and the patient have to be blinded 7 . In the P100 study, these strict methodological criteria do not apply. This makes it difficult to examine, for example, whether people alter their behavior in response to just being observed (the Hawthorne effect). Proponents of preventive precision medicine may argue that there are other ways of providing evidence for treatment efficacy as the number of measured variables increases and the number of research subjects that are similar enough for a personalized approach moves toward n = 1. This may involve continuous monitoring to observe significant changes in each particular person. The prospect of using such big data 'narratives' as evidence is intriguing. However, the P100 study fruitfully highlights how important epistemological and methodological questions must be clarified and answered before it is clear how one determines who is at risk and what treatments actually work.
In general, it is not clear what the key concepts of "actionability" or "clinical utility" refer to in the P100 study. We do not know how much action the participants were actually able to take when faced with "actionable possibilities, " nor how useful it was for them. The competence of the health coaches and the rationale for their "personalized" health recommendations are unknown, although the latter are described as being "evidence-based" and mostly consist of advice on diet, exercise, stress management and dietary supplements, or physician referral.
Importantly, the effects are measured mostly in terms of correction of surrogate endpoints. As a general point, such changes provide no guarantee for changes either in the hard endpoints of morbidity and mortality or in quality of life. As an example, a study carrying out a 10-year follow-up on the large, 5-year Inter99 study 8 -an investigation that tested lifestyle counseling on the basis of screening for risk
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factors-showed no significant difference between the intervention and control groups with respect to ischemic heart disease, stroke or mortality, despite successful changes in risk factors as in the P100 study 9 .
In P100, changes in vitamin D levels and markers for prediabetes are interpreted as evidence of health benefits. Eighty-eight percent of the participants were labeled as out of range at baseline in their vitamin D levels. Although these participants managed to increase their vitamin D levels by 7.2 ng/mL per round (of quarterly testing), it is questionable whether vitamin D supplements change hard endpoints 10 .
As another notable figure, 48% of the previously well individuals were deemed to have "out-of-range" HbA1c (glycated hemoglobin) levels and were labeled as prediabetic. Again, what these participants would gain from lowering HbA1c by 0.085% per round is unclear.
A third example is mercury levels. It is unclear how valid and useful it is to label 81 out of 108 participants with a mercury problem that on average was lowered by 0.002 μg/g per round.
More generally, vitamin D deficiency and prediabetes are examples of controversies in preventive medicine, having been criticized for questionable clinical utility, overmedicalization and unsustainable burdens on the healthcare system 11, 12 .
One case story is given special attention as evidence of potential benefit in the P100 publication 3 . A 65-year-old male presented symptoms to his physician and was found to have abnormally high ferritin. Genetic testing showed that he was homozygous for the primary genetic risk factor for hemochromatosis. In a commentary 4 , Butte claims that this particular example teaches us that "genomes can provide useful medical information to healthy individuals. " However, testing after experience of symptoms is a very different matter from screening asymptomatic people, which is what the P100 is otherwise about. It is not clear that the man would have had worse treatment or prognosis with regular primary care as this would include targeted tests in symptomatic people that can uncover high ferritin levels. High ferritin levels would in turn normally lead to genetic testing and appropriate treatment. It should also be noted that generalized screening of asymptomatic individuals for hereditary hemochromatosis is yet another controversial case in preventive medicine 13 .
Another important question is whether precision medicine can actually "empower" people to change their lifestyles in response to risk information. Although there are studies showing some positive results, a general trend in available evidence is that lifestyle interventions and health checks among the apparently healthy are of limited benefit 8, 9, [14] [15] [16] . One common and difficult challenge is that people simply often do not follow recommendations. Proponents of preventative precision medicine may argue that a personalized approach is needed precisely to provide the individual with more accurate risk assessments and advice so that they may change their behaviors according to their particular case. However, a recent systematic review with meta-analysis has showed no clear evidence for a substantial positive impact of communicating individualized genetic risks of disease on risk-reducing health behavior 15 .
P4 medicine now promises to change this picture through continual, multi-level feedback on personal health. However, the P100 study illustrates the fundamental challenges the approach may face: only 64% of the participants complied with Fitbit activity tracking for 40 days out of 9 months, and even fewer for sleep tracking-a striking result considering that the participants (largely middle-class volunteers) were presumably unusually motivated. The prospect of major benefits from preventive precision medicine should also be considered in light of increasing evidence that risk information and extensive self-tracking generally have little effect on health-related actions 17, 18 . This is not to say that counseling or coaching based on risk estimates and screening does not has an effect for some people, as several studies show 9 . However, taken together, such results call for modesty concerning the prospects of extensive self-monitoring improving population health greatly, especially in providing strategies that benefit those who live their lives in health-detrimental environmental situations, who are at high risk and in the greatest need of medical care 19 . As the authors of the abovementioned Inter99 study state, the implication of the generally weak results of screening and lifestyle counseling is that health behavior depends on the individual's social context and life conditions; interventions should therefore be mostly be structural, rather than targeted at individuals 9 .
Although extensive measurement and testing may have some benefits, these must be weighed against harms and costs. The P100 study seems mostly geared toward showing benefits, but we must also consider possible downsides of this approach on a theoretical basis.
The most important finding in the P100 study may be that every one of the 108 participants was found to have multiple "actionable possibilities" and thus was labeled as in need of medical attention. To define every single person as at risk is not very precise. It is also potentially harmful. To underscore, these people considered themselves well at baseline, but upon entering the study, they were all regarded as in suboptimal health. This entails a change in identity and may result in pathologization and worry 20, 21 .
Crucially, the P100 highlights the problem of overdiagnosis (i.e., discovery of real but asymptomatic abnormalities that will never become symptomatic health problems). Overdiagnosis is a serious problem because it often leads to costs and harms associated with overtreatment and further over-testing, while it cannot, by definition, benefit those who would never develop symptomatic disease.
Recent meta-analyses show that the problem of overdiagnosis is due not only to a lack of predictive power in medical testing, but also to medical overactivity more generally. The problem increases with lowered diagnostic thresholds, intensified screening for early disease and risk states, diagnostic technologies with higher resolution, and more frequent and intensified measurements of multiple parameters 22 . The P100 approach includes all of these potential drivers of overdiagnosis. Previous papers commenting on the P100 study have raised concerns about the increased risk of overdiagnosis 1, 23, 24 . The P100 researchers acknowledge false-positive tests, but have not addressed overdiagnosis, either in previous papers 3 or in the current publication 25 .
We should also consider opportunity costs: the P100 strategy means a large investment for each participant (and society), in terms of money, time and attention. What could have been gained in terms of health and other benefits had the resources been used otherwise?
What have we learned from the P100 study? This question is difficult to answer. The study does not follow available guidelines for assessment of public health impact of medical testing. This is particularly disconcerting as the project is the pilot for the much larger 100K Wellness Project. P100 promotes a novel concept that is branded as "scientific wellness." However, in practice the study represents a form of data-driven screening for early disease and risk states that entails an unprecedented medicalization in terms of measurements and interventions 24 . The benefit the previously well participants reap from this is literally in the (data) clouds.
The P100 study highlights the need to discuss how high a price we are willing to pay to explore the potential of P4 medicine and whether we have unrealistic expectations for the new technologies. Overstating the potential may influence personal and
political choices and divert attention and resources from strategies that may be more effective. Researchers who develop technologies for preventive medicine should take its profound challenges seriously-especially overdiagnosis. To make informed choices about the future of healthcare, we need studies that substantiate what we may call actionable evidence; that is, studies showing changes in hard endpoints that take seriously the risk of unintentional harm. In the context of P4 medicine or precision medicine, the balance between promises and evidence should be better calibrated.
Price et al. reply:
The Pioneer 100 Wellness Project (P100) 1 was the first example of generating personal, dense, dynamic data clouds across a population, following in the footsteps of several other groundbreaking efforts on single individuals 2-4 . We developed the logistical and technological framework to collect and analyze longitudinal health data combined with genetic data. We analyzed the data clouds to generate an initial multi-omic correlation network across all these domains (genome, proteome, metabolome, microbiome, clinical laboratory and lifestyle data), extract communities of related analytes associated with physiology and disease, and identify molecular correlates of polygenic risk. We also curated actionable information from these data sets and developed coaching strategies to communicate personalized information to individuals, helping to improve clinical blood biomarkers in our cohort and observe disease-to-wellness transitions as the quality of individuals' health improved.
Vogt et al. 5 make several arguments about the promise and challenges of precision or P4 (predictive, preventive, personalized and participatory) medicine, using our study as a window through which to judge future applications to clinical medicine. They acknowledge the P100 as a landmark study that sets the stage for the US National Institutes of Health (NIH) All of Us program 6 , but then go on to extrapolate from our study a future in which evidence-based medicine is discarded in favor of unproven claims and unnecessary interventions.
In truth, we have barely begun to densely phenotype the human body over time and systematically. It is important to emphasize that the goals for the P100 study were focused on discovery rather than clinical practice 7 . There is still much to learn about human biology, including how the combination of genetics, the microbiome, environment and lifestyle synergistically influences health and disease through dynamic changes in the body, as well as the optimal strategies for communicating this information to individuals in a manner that leads to behavior change. Learning better how to translate data to actionable possibilities will enhance personalized interventions that can optimize wellness and minimize disease risk. When medical interventions are necessary, such data (perhaps in the future collected on a real-time basis using smart technology) could identify the optimal timing and dosage of medication, replacing the current trial-and-error cycle of dosage versus clinical efficacy. We certainly agree that overdiagnosis and overtreatment are important issues when providing medical care. Indeed, a major goal of personalized medicine is to reduce unnecessary treatment, which is an enormous current problem. Of the top ten most commonly prescribed drugs in the United States, the most effective benefits only 1 in 4 patients, and the least effective benefits only 1 in 25, which has been referred to as our current state of 'imprecision medicine' 8 . Furthermore, we concur that personalized approaches for disease prevention must be guided by good evidence. 'Scientific wellness' , a quantitative or data-informed approach to improving health and avoiding disease, should be embraced by the medical research community, with funding allocated to study it more rigorously.
Vogt et al. state that, in a true 'n-of-1' trial, changes in clinical biomarkers are biased if the individual knows they are taking an experimental therapy (i.e., the Hawthorne effect). In the case of a true experimental therapy (for example, an experimental drug intervention) this is undoubtedly true. However, as Vogt et al. remind us, the P100 study focused on actionable recommendations involving diet, exercise, stress management, dietary supplements and physician referral-not experimental therapy. In fact, personal data collected throughout the P100 study were explicitly used to motivate behavior change in each individual. In this scenario, the Hawthorne effect is a feature, not a bug. That being said, we do not categorize the P100 as an 'n-of-1' trial, as Vogt et al. suggest. Most of the assays collected throughout the P100 were not used for coaching or interventions of any kind. Actionable recommendations were enabled from personal data but were ultimately derived from evidence-based guidelines, meta-analyses or clinical trials, and coaches were licensed allied health professionals (registered dietitian nutritionists with experience in promoting behavior change) working under the supervision of a physician.
Vogt et al. raise concerns about relying on surrogate endpoints, rather than morbidity and mortality endpoints, and mention that the Inter99 study found no evidence that lifestyle interventions had an impact on ischemic heart disease, stroke or mortality over a 10-year period 9 . We acknowledge C O R R E S P O N D E N C E
